Sustained release small molecule drug formulation

Patent metadata

Field	Value
Publication number	US-9597402-B2
Application number	US-201514701173-A
Country	US
Kind code	B2
Filing date	Apr 30, 2015
Priority date	Sep 30, 2005
Publication date	Mar 21, 2017
Grant date	Mar 21, 2017

Abstract

An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having C max to C min ratio less than 200 and lag time less than 0.2.

First claim

What is claimed is:

1. A formulation, comprising:
a copolymer of lactic acid and glycolic acid having a number average molecular weight ranging from 1000 Daltons to 120,000 Daltons;
an organic solvent combined with the copolymer to form a viscous gel, the organic solvent being selected from benzyl alcohol, benzyl benzoate, ethyl benzoate, ethyl hydroxide, N-methyl-2-pyrrolidone, and mixtures thereof; and
risperidone base in particle form incorporated in the viscous gel, wherein the particles have an average particle size ranging from 0.1 μm to 125 μm,
wherein the copolymer and the organic solvent comprise a vehicle, the copolymer is present in the vehicle in an amount ranging from 40% to 55% by weight, and the organic solvent is present in the vehicle in an amount ranging from 45% to 60% by weight.

2. The formulation of claim 1 , wherein the copolymer of lactic acid and glycolic acid has a monomer ratio of lactic acid to glycolic acid ranging from about 100:0 to 60:40.

3. The formulation of claim 1 , wherein the copolymer of lactic acid and glycolic acid has a monomer ratio of lactic acid to glycolic acid ranging from 100:0 to 75:25.

4. The formulation of claim 1 , wherein the copolymer has a number average molecular weight ranging from 1000 Daltons to 30,000 Daltons.

5. The formulation of claim 1 , wherein the copolymer has a number average molecular weight ranging from 5000 Daltons to 30,000 Daltons.

6. The formulation of claim 1 , wherein the organic solvent comprises N-methyl-2-pyrrolidone.

7. The formulation of claim 1 , wherein the risperidone base is present in the formulation in an amount ranging from 5 wt % to 40 wt %.

8. The formulation of claim 1 , wherein the risperidone base is present in the formulation in an amount ranging from 10 wt % to 30 wt %.

9. The formulation of claim 1 , wherein the copolymer of lactic acid and glycolic acid has a monomer ratio of lactic acid to glycolic acid ranging from about 100:0 to 60:40, and the copolymer has a number average molecular weight ranging from 1000 Daltons to 30,000 Daltons.

10. The formulation of claim 1 , wherein the copolymer of lactic acid and glycolic acid has a monomer ratio of lactic acid to glycolic acid ranging from 100:0 to 75:25, and the copolymer has a number average molecular weight ranging from 5000 Daltons to 30,000 Daltons.

11. The formulation of claim 1 , wherein the copolymer of lactic acid and glycolic acid has a monomer ratio of lactic acid to glycolic acid ranging from about 100:0 to 60:40, the copolymer has a number average molecular weight ranging from 1000 Daltons to 30,000 Daltons, and the organic solvent comprises N-methyl-2-pyrrolidone.

12. The formulation of claim 1 , wherein the copolymer of lactic acid and glycolic acid has a monomer ratio of lactic acid to glycolic acid ranging from 100:0 to 75:25, the copolymer has a number average molecular weight ranging from 5000 Daltons to 30,000 Daltons, and the organic solvent comprises N-methyl-2-pyrrolidone.

13. The formulation of claim 1 , wherein the organic solvent comprises N-methyl-2-pyrrolidone, and the risperidone base is present in the formulation in an amount ranging from 10 wt % to 30 wt %.

14. The formulation of claim 1 , wherein the copolymer of lactic acid and glycolic acid has a monomer ratio of lactic acid to glycolic acid ranging from about 100:0 to 60:40, the copolymer has a number average molecular weight ranging from 1000 Daltons to 30,000 Daltons, the organic solvent comprises N-methyl-2-pyrrolidone, and the risperidone base is present in the formulation in an amount ranging from 10 wt % to 30 wt %.

15. The formulation of claim 1 , wherein the copolymer of lactic acid and glycolic acid has a monomer ratio of lactic acid to glycolic acid ranging from 100:0 to 75:25, the copolymer has a number average molecular weight ranging from 5000 Daltons to 30,000 Daltons, the organic solvent comprises N-methyl-2-pyrrolidone, and the risperidone base is present in the formulation in an amount ranging from 10 wt % to 30 wt %.

16. The formulation of claim 1 , wherein the copolymer of lactic acid and glycolic acid has a monomer ratio of lactic acid to glycolic acid ranging from 100:0 to 75:25, the organic solvent comprises N-methyl-2-pyrrolidone, and the risperidone base is present in the formulation in an amount ranging from 10 wt % to 30 wt %.

17. The formulation of claim 1 , wherein the formulation exhibits a lag time less than 0.2.

Assignees

• Durect Corp

Inventors

• Luk Andrew S
• Junnarkar Gunjan H
• Chen Guohua

Classifications

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61K47/10

  Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers · CPC title

• A61K47/22

  Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones · CPC title

• A61K47/14

  Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters · CPC title

• A61K9/0024

  Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L) · CPC title